Niclosamide

By Targets:	Antibiotic (7) Apoptosis (1) CXCR (2) Fluorescent Dye (1) GCGR (2) Isotope-Labeled Compounds (1) Neuropeptide Y Receptor (2) Parasite (7) SARS-CoV (3) STAT (8)
By Research Areas:	Cancer (9) Endocrinology (1) Infection (8) Metabolic Disease (3) Neurological Disease (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0497

*Niclosamide* Maximum Cited Publications 20 Publications Verification BAY2353	STAT Parasite Antibiotic	Infection Cancer
Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

HY-B0497C

Niclosamide olamine Maximum Cited Publications 20 Publications Verification BAY2353 olamine	STAT Parasite Antibiotic	Infection Cancer
Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research . Niclosamide olamin is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .

HY-B0497B

Niclosamide monohydrate BAY2353 monohydrate	STAT Antibiotic Parasite	Infection Cancer
Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research . Niclosamide monohydrate is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .

HY-B0497A

Niclosamide sodium BAY2353 sodium	Antibiotic STAT Parasite	Infection Cancer
Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research . Niclosamide sodium is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells .

HY-B0497G

Niclosamide BAY2353	Antibiotic Parasite STAT	Cancer
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

HY-B0497BS

Niclosamide-13C6 monohydrate BAY2353-¹³C₆ monohydrate	STAT Parasite Antibiotic
Niclosamide- ¹³C₆ (monohydrate) is the ¹³C labeled Niclosamide monohydrate[1]. Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research[2]. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[5]. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[3][4][6].

HY-B0497S1

Niclosamide-13C6 BAY2353-¹³C₆	Isotope-Labeled Compounds STAT Parasite Antibiotic	Infection Cancer
Niclosamide- ¹³C₆ is the ¹³C₆ labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.

HY-144771

SARS-CoV-2-IN-14	SARS-CoV	Infection
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144772

SARS-CoV-2-IN-15	SARS-CoV	Infection
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144770

SARS-CoV-2-IN-13	SARS-CoV	Infection
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-W369099

HJC0152 free base	STAT Apoptosis	Cancer
HJC0152 (free base) is an orally active and potent inhibitor of STAT3. HJC0152 (free base) inhibits cell cycle progression and induces apoptosis. HJC0152 (free base) significantly suppresses MDA-MB-231 xenograft tumor growth in mice .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

Cat. No.	Product Name	Type

HY-B0497G

Niclosamide (GMP) BAY2353 (GMP)	Fluorescent Dye
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

Niclosamide (GMP)

BAY2353 (GMP)

Fluorescent Dye

Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

Cat. No.	Product Name	Type

HY-B0497G

Niclosamide (GMP) BAY2353 (GMP)	Biochemical Assay Reagents
Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

Niclosamide (GMP)

BAY2353 (GMP)

Biochemical Assay Reagents

Niclosamide (GMP) is Niclosamide (HY-B0497) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research . Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells . Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells .

Cat. No.	Product Name	Target	Research Area

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P4757

N1-Glutathionyl-spermidine disulfide

Peptides Others

N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
HY-P10026

Nisotirostide

LY-3457263
Peptides Metabolic Disease

Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

N1-Glutathionyl-spermidine disulfide	Peptides	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

Nisotirostide LY-3457263	Peptides	Metabolic Disease
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P10016

Pegmolesatide HS-20039; EPO-018B	Peptides	Endocrinology
Pegmolesatide(HS-20039; EPO-018B) a synthetic peptide-based erythropoiesis-stimulating agent, can be used for ??the study of anemia in chronic kidney disease .

Cat. No.	Product Name	Chemical Structure

HY-B0497S1

Niclosamide-13C6
Niclosamide- ¹³C₆ is the ¹³C₆ labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.

HY-B0497BS

Niclosamide-13C6 monohydrate
Niclosamide- ¹³C₆ (monohydrate) is the ¹³C labeled Niclosamide monohydrate[1]. Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research[2]. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[5]. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[3][4][6].

Niclosamide-13C6 monohydrate

Niclosamide- ¹³C₆ (monohydrate) is the ¹³C labeled Niclosamide monohydrate[1]. Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used in parasitic infection research[2]. Niclosamide monohydrate is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[5]. Niclosamide monohydrate has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[3][4][6].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds